Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division. The patent covers expression of the human Klotho protein for treatment of neuromuscular diseases, including constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
This patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. The company stated that the patent provides important protection for its gene therapy approach.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on exploration and development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland; and Biotech, including the KLTO-202 program for ALS. The company’s strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision.
For the full press release, visit https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
This patent grant is a significant milestone for Greenland Mines as it secures key intellectual property in the growing field of gene therapy. The Klotho protein has been studied for its potential anti-aging and neuroprotective effects, and this patent could pave the way for novel treatments for devastating diseases like ALS. Investors and stakeholders will be watching the progress of the KLTO-202 program closely.
